Press "Enter" to skip to content

Human Insulin Market 2019 Significant Growth Rate by Industry Size, Share, Market Dynamics, Development Status of Key Players Forecast to 2024

Human

The “Human Insulin Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Human Insulin industry. The information available in the Human Insulin market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Human Insulin market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Human Insulin Market:

  • Novo Nordisk AS
  • Sanofi Aventis
  • Eli Lilly
  • Biocon
  • Pfizer
  • Julphar
  • Exir
  • Sedico
  • Wockhardt

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999756

    Market Overview:

  • The global human insulin market is expected to register a CAGR of 4.93% during the forecast period of 2019 – 2024 and is estimated to reach USD 25.7 billion by 2019.
  • Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world.
  • Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes.
  • Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.

    Scope of the Report:

  • The market is segmented by product type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins) and geography.<

    Reasons for Buying Human Insulin Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999756

    Key Market Trends: – Growing Obesity and Diabetes Prevalence of Type 2, Especially in Developing Countries

    The exact cause of Type 1 diabetes is unknown, but Type 2 diabetes is caused by lifestyle changes happening daily. The prevalence rate of Type 2 diabetes has quadrupled, when compared to 40 years ago. Although oral drugs are considered as a standard care treatment for Type 2 patients, there has been a rise in the need for using insulin, along with the conventional medication, in order to help stabilize blood glucose levels. This trend has attracted many players, both local and international, to enter into the biosimilar market.
    The prevalence of Type 2 diabetes mellitus (T2DM) has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and the primary risk factor for T2DM. Diabetes ranks among the fast-growing chronic diseases in the United States.
    India is among the top three countries with a high incidence of diabetes. Many reports and surveys have documented a drastic increase in the diabetic population based on lifestyle habits. Significant urbanization has enabled physical inactivity and diabetes is a major health concern.
    The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients’ use, curbing out maximum side effects and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, which may drive the global market for insulin therapeutics.

    North America Dominates the Market

    North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region, because of a sedentary lifestyle and launch of new drugs in the region.
    The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself.
    Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of obesity and rising awareness regarding diabetes care in the region.

    Human Insulin Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999756

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Human Insulin Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Product Type
    5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.1.1.1 Lantus
    5.1.1.2 Levemir
    5.1.1.3 Toujeo
    5.1.1.4 Tresiba
    5.1.1.5 Basaglar
    5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2024)
    5.1.2.1 NovoRapid/Novolog
    5.1.2.2 Humalog
    5.1.2.3 Apidra
    5.1.3 Traditional Human Insulins (Value and Volume, 2012-2024)
    5.1.3.1 Novolin/Actrapid/Insulatard
    5.1.3.2 Humulin
    5.1.3.3 Insuman
    5.1.4 Combination Insulins (Value and Volume, 2012-2024)
    5.1.4.1 NovoMix
    5.1.4.2 Ryzodeg
    5.1.4.3 Xultophy
    5.1.5 Biosimilar Insulins (Value and Volume, 2012-2024)
    5.1.5.1 Insulin Glargine Biosimilars
    5.1.5.2 Human Insulin Biosimilars
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume, 2012-2024)
    5.2.1.1.1 Basal or Long-acting Insulins
    5.2.1.1.2 Bolus or Fast-acting Insulins
    5.2.1.1.3 Traditional Human Insulins
    5.2.1.1.4 Combination Insulins
    5.2.1.1.5 Biosimilar Insulins
    5.2.1.2 Canada (Value and Volume, 2012-2024)
    5.2.1.2.1 Basal or Long-acting Insulins
    5.2.1.2.2 Bolus or Fast-acting Insulins
    5.2.1.2.3 Traditional Human Insulins
    5.2.1.2.4 Combination Insulins
    5.2.1.2.5 Biosimilar Insulins
    5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
    5.2.1.3.1 Basal or Long-acting Insulins
    5.2.1.3.2 Bolus or Fast-acting Insulins
    5.2.1.3.3 Traditional Human Insulins
    5.2.1.3.4 Combination Insulins
    5.2.1.3.5 Biosimilar Insulins
    5.2.2 Europe
    5.2.2.1 France (Value and Volume, 2012-2024)
    5.2.2.1.1 Basal or Long-acting Insulins
    5.2.2.1.2 Bolus or Fast-acting Insulins
    5.2.2.1.3 Traditional Human Insulins
    5.2.2.1.4 Combination Insulins
    5.2.2.1.5 Biosimilar Insulins
    5.2.2.2 Germany (Value and Volume, 2012-2024)
    5.2.2.2.1 Basal or Long-acting Insulins
    5.2.2.2.2 Bolus or Fast-acting Insulins
    5.2.2.2.3 Traditional Human Insulins
    5.2.2.2.4 Combination Insulins
    5.2.2.2.5 Biosimilar Insulins
    5.2.2.3 Italy (Value and Volume, 2012-2024)
    5.2.2.3.1 Basal or Long-acting Insulins
    5.2.2.3.2 Bolus or Fast-acting Insulins
    5.2.2.3.3 Traditional Human Insulins
    5.2.2.3.4 Combination Insulins
    5.2.2.3.5 Biosimilar Insulins
    5.2.2.4 Spain (Value and Volume, 2012-2024)
    5.2.2.4.1 Basal or Long-acting Insulins
    5.2.2.4.2 Bolus or Fast-acting Insulins
    5.2.2.4.3 Traditional Human Insulins
    5.2.2.4.4 Combination Insulins
    5.2.2.4.5 Biosimilar Insulins
    5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
    5.2.2.5.1 Basal or Long-acting Insulins
    5.2.2.5.2 Bolus or Fast-acting Insulins
    5.2.2.5.3 Traditional Human Insulins
    5.2.2.5.4 Combination Insulins
    5.2.2.5.5 Biosimilar Insulins
    5.2.2.6 Russia (Value and Volume, 2012-2024)
    5.2.2.6.1 Basal or Long-acting Insulins
    5.2.2.6.2 Bolus or Fast-acting Insulins
    5.2.2.6.3 Traditional Human Insulins
    5.2.2.6.4 Combination Insulins
    5.2.2.6.5 Biosimilar Insulins
    5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
    5.2.2.7.1 Basal or Long-acting Insulins
    5.2.2.7.2 Bolus or Fast-acting Insulins
    5.2.2.7.3 Traditional Human Insulins
    5.2.2.7.4 Combination Insulins
    5.2.2.7.5 Biosimilar Insulins
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume, 2012-2024)
    5.2.3.1.1 Basal or Long-acting Insulins
    5.2.3.1.2 Bolus or Fast-acting Insulins
    5.2.3.1.3 Traditional Human Insulins
    5.2.3.1.4 Combination Insulins
    5.2.3.1.5 Biosimilar Insulins
    5.2.3.2 Brazil (Value and Volume, 2012-2024)
    5.2.3.2.1 Basal or Long-acting Insulins
    5.2.3.2.2 Bolus or Fast-acting Insulins
    5.2.3.2.3 Traditional Human Insulins
    5.2.3.2.4 Combination Insulins
    5.2.3.2.5 Biosimilar Insulins
    5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
    5.2.3.3.1 Basal or Long-acting Insulins
    5.2.3.3.2 Bolus or Fast-acting Insulins
    5.2.3.3.3 Traditional Human Insulins
    5.2.3.3.4 Combination Insulins
    5.2.3.3.5 Biosimilar Insulins
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume, 2012-2024)
    5.2.4.1.1 Basal or Long-acting Insulins
    5.2.4.1.2 Bolus or Fast-acting Insulins
    5.2.4.1.3 Traditional Human Insulins
    5.2.4.1.4 Combination Insulins
    5.2.4.1.5 Biosimilar Insulins
    5.2.4.2 South Korea (Value and Volume, 2012-2024)
    5.2.4.2.1 Basal or Long-acting Insulins
    5.2.4.2.2 Bolus or Fast-acting Insulins
    5.2.4.2.3 Traditional Human Insulins
    5.2.4.2.4 Combination Insulins
    5.2.4.2.5 Biosimilar Insulins
    5.2.4.3 China (Value and Volume, 2012-2024)
    5.2.4.3.1 Basal or Long-acting Insulins
    5.2.4.3.2 Bolus or Fast-acting Insulins
    5.2.4.3.3 Traditional Human Insulins
    5.2.4.3.4 Combination Insulins
    5.2.4.3.5 Biosimilar Insulins
    5.2.4.4 India (Value and Volume, 2012-2024)
    5.2.4.4.1 Basal or Long-acting Insulins
    5.2.4.4.2 Bolus or Fast-acting Insulins
    5.2.4.4.3 Traditional Human Insulins
    5.2.4.4.4 Combination Insulins
    5.2.4.4.5 Biosimilar Insulins
    5.2.4.5 Australia (Value and Volume, 2012-2024)
    5.2.4.5.1 Basal or Long-acting Insulins
    5.2.4.5.2 Bolus or Fast-acting Insulins
    5.2.4.5.3 Traditional Human Insulins
    5.2.4.5.4 Combination Insulins
    5.2.4.5.5 Biosimilar Insulins
    5.2.4.6 Vietnam (Value and Volume, 2012-2024)
    5.2.4.6.1 Basal or Long-acting Insulins
    5.2.4.6.2 Bolus or Fast-acting Insulins
    5.2.4.6.3 Traditional Human Insulins
    5.2.4.6.4 Combination Insulins
    5.2.4.6.5 Biosimilar Insulins
    5.2.4.7 Malaysia (Value and Volume, 2012-2024)
    5.2.4.7.1 Basal or Long-acting Insulins
    5.2.4.7.2 Bolus or Fast-acting Insulins
    5.2.4.7.3 Traditional Human Insulins
    5.2.4.7.4 Combination Insulins
    5.2.4.7.5 Biosimilar Insulins
    5.2.4.8 Indonesia (Value and Volume, 2012-2024)
    5.2.4.8.1 Basal or Long-acting Insulins
    5.2.4.8.2 Bolus or Fast-acting Insulins
    5.2.4.8.3 Traditional Human Insulins
    5.2.4.8.4 Combination Insulins
    5.2.4.8.5 Biosimilar Insulins
    5.2.4.9 Philippines (Value and Volume, 2012-2024)
    5.2.4.9.1 Basal or Long-acting Insulins
    5.2.4.9.2 Bolus or Fast-acting Insulins
    5.2.4.9.3 Traditional Human Insulins
    5.2.4.9.4 Combination Insulins
    5.2.4.9.5 Biosimilar Insulins
    5.2.4.10 Thailand (Value and Volume, 2012-2024)
    5.2.4.10.1 Basal or Long-acting Insulins
    5.2.4.10.2 Bolus or Fast-acting Insulins
    5.2.4.10.3 Traditional Human Insulins
    5.2.4.10.4 Combination Insulins
    5.2.4.10.5 Biosimilar Insulins
    5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
    5.2.4.11.1 Basal or Long-acting Insulins
    5.2.4.11.2 Bolus or Fast-acting Insulins
    5.2.4.11.3 Traditional Human Insulins
    5.2.4.11.4 Combination Insulins
    5.2.4.11.5 Biosimilar Insulins
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
    5.2.5.1.1 Basal or Long-acting Insulins
    5.2.5.1.2 Bolus or Fast-acting Insulins
    5.2.5.1.3 Traditional Human Insulins
    5.2.5.1.4 Combination Insulins
    5.2.5.1.5 Biosimilar Insulins
    5.2.5.2 Iran (Value and Volume, 2012-2024)
    5.2.5.2.1 Basal or Long-acting Insulins
    5.2.5.2.2 Bolus or Fast-acting Insulins
    5.2.5.2.3 Traditional Human Insulins
    5.2.5.2.4 Combination Insulins
    5.2.5.2.5 Biosimilar Insulins
    5.2.5.3 Egypt (Value and Volume, 2012-2024)
    5.2.5.3.1 Basal or Long-acting Insulins
    5.2.5.3.2 Bolus or Fast-acting Insulins
    5.2.5.3.3 Traditional Human Insulins
    5.2.5.3.4 Combination Insulins
    5.2.5.3.5 Biosimilar Insulins
    5.2.5.4 Oman (Value and Volume, 2012-2024)
    5.2.5.4.1 Basal or Long-acting Insulins
    5.2.5.4.2 Bolus or Fast-acting Insulins
    5.2.5.4.3 Traditional Human Insulins
    5.2.5.4.4 Combination Insulins
    5.2.5.4.5 Biosimilar Insulins
    5.2.5.5 South Africa (Value and Volume, 2012-2024)
    5.2.5.5.1 Basal or Long-acting Insulins
    5.2.5.5.2 Bolus or Fast-acting Insulins
    5.2.5.5.3 Traditional Human Insulins
    5.2.5.5.4 Combination Insulins
    5.2.5.5.5 Biosimilar Insulins
    5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
    5.2.5.6.1 Basal or Long-acting Insulins
    5.2.5.6.2 Bolus or Fast-acting Insulins
    5.2.5.6.3 Traditional Human Insulins
    5.2.5.6.4 Combination Insulins
    5.2.5.6.5 Biosimilar Insulins

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk AS
    7.1.2 Sanofi Aventis
    7.1.3 Eli Lilly
    7.1.4 Biocon
    7.1.5 Pfizer
    7.1.6 Julphar
    7.1.7 Exir
    7.1.8 Sedico
    7.1.9 Wockhardt
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk AS
    7.2.2 Sanofi Aventis
    7.2.3 Eli Lilly
    7.2.4 Other Companies

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Car Care Products Market 2019: Industry Size & Share, Business Strategies, Growth Analysis, Regional Demand, Revenue, Key Manufacturers and 2024 Forecast Research Report

    Glass Packaging Market Size and Share 2019 | Global Industry Analysis By Trends, Future Demands, Growth Factors, Emerging Technologies, Prominent Players and Forecast Till 2024

    Neuroendocrine Tumor Treatment Market 2019 Analysis and Outlook, Demand, Industry Size, Future Trends and Industry Growth Research Report 2025

    Semiconductor Deposition Market Growth by Manufacturers, Regions, Type and Application, Market Size, Forecast Analysis to 2025